AU2002336749A1 - Tricyclic indole derivatives as 5-ht ligands - Google Patents

Tricyclic indole derivatives as 5-ht ligands

Info

Publication number
AU2002336749A1
AU2002336749A1 AU2002336749A AU2002336749A AU2002336749A1 AU 2002336749 A1 AU2002336749 A1 AU 2002336749A1 AU 2002336749 A AU2002336749 A AU 2002336749A AU 2002336749 A AU2002336749 A AU 2002336749A AU 2002336749 A1 AU2002336749 A1 AU 2002336749A1
Authority
AU
Australia
Prior art keywords
ligands
indole derivatives
tricyclic indole
tricyclic
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002336749A
Other languages
English (en)
Inventor
Jian-Min Fu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Pharmacia and Upjohn Co
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn Co, Upjohn Co filed Critical Pharmacia and Upjohn Co
Publication of AU2002336749A1 publication Critical patent/AU2002336749A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2002336749A 2001-09-21 2002-09-19 Tricyclic indole derivatives as 5-ht ligands Abandoned AU2002336749A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32366601P 2001-09-21 2001-09-21
US60/323,666 2001-09-21
PCT/US2002/030089 WO2003024976A2 (en) 2001-09-21 2002-09-19 Tricyclic indole derivatives as 5-ht ligands

Publications (1)

Publication Number Publication Date
AU2002336749A1 true AU2002336749A1 (en) 2003-04-01

Family

ID=23260193

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002336749A Abandoned AU2002336749A1 (en) 2001-09-21 2002-09-19 Tricyclic indole derivatives as 5-ht ligands

Country Status (8)

Country Link
US (1) US6887868B2 (enExample)
EP (1) EP1429776A2 (enExample)
JP (1) JP2005527477A (enExample)
AU (1) AU2002336749A1 (enExample)
BR (1) BR0212676A (enExample)
CA (1) CA2460126A1 (enExample)
MX (1) MXPA04002615A (enExample)
WO (1) WO2003024976A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2004000826A1 (es) 2003-04-25 2005-03-04 Pfizer Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
WO2006022420A1 (ja) 2004-08-25 2006-03-02 Takeda Pharmaceutical Company Limited 腹圧性尿失禁の予防・治療剤及びそのスクリーニング方法
AR059356A1 (es) * 2006-02-14 2008-03-26 Astrazeneca Ab Nuevos radioligandos
WO2007132841A1 (ja) 2006-05-16 2007-11-22 Takeda Pharmaceutical Company Limited 縮合複素環化合物およびその用途
JP5520051B2 (ja) 2007-11-15 2014-06-11 武田薬品工業株式会社 縮合ピリジン誘導体およびその用途
WO2011071136A1 (ja) 2009-12-11 2011-06-16 アステラス製薬株式会社 線維筋痛症治療剤
US9216998B2 (en) * 2012-02-15 2015-12-22 Janssen Pharmaceutica Nv Tricyclic indole derivatives useful endothelial lipase inhibitors
DK3684767T3 (da) 2017-09-22 2024-07-15 Jubilant Epipad LLC Heterocykliske forbindelser som pad-inhibitorer
AU2018352142B2 (en) 2017-10-18 2022-08-25 Jubilant Epipad LLC Imidazo-pyridine compounds as PAD inhibitors
CN111386265A (zh) 2017-11-06 2020-07-07 朱比连特普罗德尔有限责任公司 作为pd1/pd-l1活化的抑制剂的嘧啶衍生物
SMT202400203T1 (it) 2017-11-24 2024-07-09 Jubilant Episcribe Llc Composti eterociclici come inibitori di prmt5
EP3733204A4 (en) 2017-12-27 2021-09-15 Takeda Pharmaceutical Company Limited THERAPEUTIC AGENT FOR URINARY INCONTINENCE OF STRESS AND FECAL INCONTINENCE
CA3093527A1 (en) 2018-03-13 2019-09-19 Jubilant Prodel LLC Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3914421A (en) 1972-06-19 1975-10-21 Endo Lab Pyridopyrrolobenzheterocycles for combatting depression
US4219550A (en) * 1978-11-09 1980-08-26 E. I. Du Pont De Nemours And Company Cis- and trans- octahydropyridopyrrolobenzheterocycles
NZ227229A (en) * 1987-12-10 1991-03-26 Duphar Int Res Indole derivatives and pharmaceutical compositions
US4938949A (en) * 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
NZ233285A (en) 1989-04-18 1992-06-25 Duphar Int Res Imidazole-substituted carbamoyl-indoles and condensed analogues thereof and pharmaceutical compositions
GB8913646D0 (en) 1989-06-14 1989-08-02 Glaxo Group Ltd Chemical compounds
HUT61548A (en) * 1990-08-27 1993-01-28 Sandoz Ag Process for producing indolonaphthyridine derivatives and pharmaceutical compositions comprising such compounds
CN1320123A (zh) * 1998-07-30 2001-10-31 日本烟草产业株式会社 二取代马来酰亚胺化合物及其医药用途
AR023574A1 (es) * 1999-04-23 2002-09-04 Pharmacia & Upjohn Co Llc Compuestos de azepinindol tetraciclico,composiciones farmaceuticas y el uso de dichos compuestos para preparar un medicamento, e intermediarios
AU5737900A (en) * 1999-06-15 2001-01-02 Du Pont Pharmaceuticals Company Substituted heterocycle fused gamma-carbolines

Also Published As

Publication number Publication date
US6887868B2 (en) 2005-05-03
US20030087883A1 (en) 2003-05-08
WO2003024976A3 (en) 2004-02-12
MXPA04002615A (es) 2004-07-08
CA2460126A1 (en) 2003-03-27
JP2005527477A (ja) 2005-09-15
EP1429776A2 (en) 2004-06-23
BR0212676A (pt) 2006-05-23
WO2003024976A2 (en) 2003-03-27

Similar Documents

Publication Publication Date Title
IL162105A0 (en) New indole derivatives as factor xainhibitors
AU5049699A (en) Phenylindole derivatives as 5-HT2A receptor ligands
AU2001231664A1 (en) Indol-3-yl derivatives
AU5633300A (en) Indole compounds
AU2002336749A1 (en) Tricyclic indole derivatives as 5-ht ligands
AU7947000A (en) Tricyclic fused-imidazole derivatives
IL160043A0 (en) Process for the preparation of indole derivatives
AU2001259051A1 (en) Piperidyindoles as serotonin receptor ligands
AU2001295455A1 (en) Indoline derivatives as 5ht2c antagonists
AU2002346507A1 (en) Benzazepine derivatives and their use as 5-ht ligands
AU1339301A (en) Novel indole compounds
AU2003217817A1 (en) Pyridinyloxy derivatives as 5-ht receptor ligands
AU2002328894A1 (en) Substituted 4-aminocyclohexanol derivatives
AU2003209114A1 (en) Pyrrolylalkylidene-hydrazinecarboximidamide derivatives as 5-hydroxytryptamine-6 ligands
IL158830A0 (en) Novel indole derivatives
AU5633800A (en) Indole compounds
AU2002332480A1 (en) Tetracyclic indole derivatives as 5-ht receptor ligands
AU2001286259A1 (en) Tricyclic indole compounds having affinity for serotonin receptor
AU2002248321A1 (en) Substituted indolines as 5-ht receptor ligands
AU2002354499A1 (en) Indole derivative
AU3634001A (en) Indole compounds
AU2003270669A1 (en) Cyclopentyl indole derivatives
AU2002332147A1 (en) Indole derivatives
HK1060880A (en) Heterocyclylalkoxy-, -alkylthio- and - alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands
HK1056561A (en) 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase